Why Cybin Stock Is Down on Monday
Shares of Cybin (NYSEMKT: CYBN), a pre-commercial drugmaker focused on developing psychedelics, fell more than 17% this morning. The company reported success with CYB003, a novel psilocybin analog, but the stock was still down 11.7% as of 11:59 a.m. EST on Monday.
Cybin's lead candidate, CYB001, is essentially psilocybin delivered under the tongue for the treatment of major depressive disorder. Today, the company reported pre-clinical results for CYB003, an orally disintegrating tablet that contains a slightly heavier version of psilocybin.
Image source: Getty Images.
Source Fool.com